Literature DB >> 17227829

Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse.

Nadira Durakovic1, Vedran Radojcic, Mario Skarica, Karl B Bezak, Jonathan D Powell, Ephraim J Fuchs, Leo Luznik.   

Abstract

Murine models of bone marrow transplantation were used to study the mechanisms governing the activation of donor lymphocyte infusions (DLIs) manifesting as lymphohematopoietic graft-versus-host (LH-GVH) and graft-versus-leukemia (GVL) reactivities. We demonstrate here that established mixed chimerism influences the potency of DLI-mediated alloreactivity only in the MHC-mismatched but not MHC-matched setting. In the MHC-matched setting, high levels (>or= 40%) of residual host chimerism correlated negatively with DLI-mediated alloreactivity irrespective of the timing of their administration, the donor's previous sensitization to host antigens, or the level of residual host APCs. In vivo administration of Toll-like receptor (TLR) ligands was required to maximize DLI-mediated LH-GVH and GVL reactivities in chimeras with low levels (<or= 15%) of residual host chimerism. In contrast, coadministration of DLI with antigen-presenting cell (APC) activators was insufficient to augment their LH-GVH response in the presence of high levels of host chimerism unless the host's T cells were transiently depleted. Together, these results show the cardinal influence of donor-host incompatibility on DLI-mediated GVH responses and suggest that in MHC-matched chimeras, the induction of optimal alloreactivity requires not only donor T cells and host APCs but also TLR ligands and in the presence of high levels of host chimerism depletion of host T cells.

Entities:  

Mesh:

Year:  2007        PMID: 17227829      PMCID: PMC1885486          DOI: 10.1182/blood-2006-09-048124

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  75 in total

Review 1.  Role of cytokines in epidermal Langerhans cell migration.

Authors:  B Wang; P Amerio; D N Sauder
Journal:  J Leukoc Biol       Date:  1999-07       Impact factor: 4.962

2.  Cutting edge: alloimmune responses against major and minor histocompatibility antigens: distinct division kinetics and requirement for CD28 costimulation.

Authors:  H K Song; H Noorchashm; Y K Lieu; S Rostami; S A Greeley; C F Barker; A Naji
Journal:  J Immunol       Date:  1999-03-01       Impact factor: 5.422

3.  CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells.

Authors:  B R Blazar; P A Taylor; M W Boyer; A Panoskaltsis-Mortari; J P Allison; D A Vallera
Journal:  J Immunol       Date:  1997-10-01       Impact factor: 5.422

Review 4.  Dendritic cells and the control of immunity.

Authors:  J Banchereau; R M Steinman
Journal:  Nature       Date:  1998-03-19       Impact factor: 49.962

5.  Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.

Authors:  B D Johnson; E E Becker; R L Truitt
Journal:  Biol Blood Marrow Transplant       Date:  1999       Impact factor: 5.742

6.  Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.

Authors:  E P Alyea; R J Soiffer; C Canning; D Neuberg; R Schlossman; C Pickett; H Collins; Y Wang; K C Anderson; J Ritz
Journal:  Blood       Date:  1998-05-15       Impact factor: 22.113

7.  T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect.

Authors:  A J Barrett; D Mavroudis; J Tisdale; J Molldrem; E Clave; C Dunbar; M Cottler-Fox; S Phang; C Carter; P Okunnieff; N S Young; E J Read
Journal:  Bone Marrow Transplant       Date:  1998-03       Impact factor: 5.483

8.  CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge.

Authors:  A M Krieg; L Love-Homan; A K Yi; J T Harty
Journal:  J Immunol       Date:  1998-09-01       Impact factor: 5.422

9.  Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease.

Authors:  S Mackinnon; E B Papadopoulos; M H Carabasi; L Reich; N H Collins; F Boulad; H Castro-Malaspina; B H Childs; A P Gillio; N A Kernan
Journal:  Blood       Date:  1995-08-15       Impact factor: 22.113

10.  High levels of a major histocompatibility complex II-self peptide complex on dendritic cells from the T cell areas of lymph nodes.

Authors:  K Inaba; M Pack; M Inaba; H Sakuta; F Isdell; R M Steinman
Journal:  J Exp Med       Date:  1997-08-29       Impact factor: 14.307

View more
  17 in total

Review 1.  Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.

Authors:  Elizabeth O Stenger; Hēth R Turnquist; Markus Y Mapara; Angus W Thomson
Journal:  Blood       Date:  2012-03-07       Impact factor: 22.113

2.  STAT3 signaling in CD4+ T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model.

Authors:  Vedran Radojcic; Maria A Pletneva; Hung-Rong Yen; Sanja Ivcevic; Angela Panoskaltsis-Mortari; Anita C Gilliam; Charles G Drake; Bruce R Blazar; Leo Luznik
Journal:  J Immunol       Date:  2009-12-07       Impact factor: 5.422

3.  Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.

Authors:  Sudipto Ganguly; Duncan B Ross; Angela Panoskaltsis-Mortari; Christopher G Kanakry; Bruce R Blazar; Robert B Levy; Leo Luznik
Journal:  Blood       Date:  2014-08-18       Impact factor: 22.113

4.  Induction of Major Histocompatibility Complex-mismatched Mouse Lung Allograft Acceptance With Combined Donor Bone Marrow: Lung Transplant Using a 12-Hour Nonmyeloablative Conditioning Regimen.

Authors:  Jeffrey M Dodd-O; Sudipto Ganguly; Ante Vulic; Angela Panoskaltsis-Mortari; John F McDyer; Leo Luznik
Journal:  Transplantation       Date:  2016-12       Impact factor: 4.939

5.  The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia.

Authors:  Ronjon Chakraverty; Megan Sykes
Journal:  Blood       Date:  2007-02-27       Impact factor: 22.113

6.  Donor T cells primed on leukemia lysate-pulsed recipient APCs mediate strong graft-versus-leukemia effects across MHC barriers in full chimeras.

Authors:  Arnab Ghosh; Wolfgang Koestner; Martin Hapke; Verena Schlaphoff; Florian Länger; Rolf Baumann; Christian Koenecke; Markus Cornberg; Karl Welte; Bruce R Blazar; Martin G Sauer
Journal:  Blood       Date:  2009-01-30       Impact factor: 22.113

Review 7.  Murine models of chronic graft-versus-host disease: insights and unresolved issues.

Authors:  Yu-Waye Chu; Ronald E Gress
Journal:  Biol Blood Marrow Transplant       Date:  2008-02-13       Impact factor: 5.742

8.  HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation.

Authors:  Amer M Zeidan; Patrick M Forde; Heather Symons; Allen Chen; B Douglas Smith; Keith Pratz; Hetty Carraway; Douglas E Gladstone; Ephraim J Fuchs; Leo Luznik; Richard J Jones; Javier Bolaños-Meade
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-01       Impact factor: 5.742

Review 9.  New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT.

Authors:  X Chang; X Zang; C Q Xia
Journal:  Bone Marrow Transplant       Date:  2015-11-23       Impact factor: 5.483

Review 10.  Toll-like receptor signaling in transplantation.

Authors:  Maria-Luisa Alegre; Daniel R Goldstein; Anita S Chong
Journal:  Curr Opin Organ Transplant       Date:  2008-08       Impact factor: 2.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.